Intravenous Aspirin Administration for Antiplatelet Therapy When Oral Therapy Is Not Possible
Intravenous acetylsalicylic acid (lysine acetylsalicylate) is used as an antiplatelet when oral aspirin is unsuitable or not possible, including acute neurologic or neuro-interventional settings. [1] Dosing depends on the clinical context and product formulation, including neuro-interventional protocols and acute coronary syndrome (ACS) studies. [1], [2], [3]
Medication Selection Algorithm
Intravenous aspirin is selected when oral aspirin cannot be administered safely or feasibly. [1] Intravenous aspirin is administered in the setting of planned neuro-interventional procedures requiring urgent antiplatelet therapy without nasogastric access. [1] Intravenous aspirin is administered as part of combination antiplatelet therapy when indicated. [1]
Recommended Intravenous Dosing
Neuro-interventional pediatric protocol (CHW)
- Loading dose: 10 mg/kg IV (intra-procedurally). [1]
- Loading dose maximum: 12.5 mg/kg or 500 mg per dose, whichever is lower. [1]
- Maintenance dose: 3 mg/kg IV once daily. [1]
- Maintenance dose maximum: 150 mg per dose. [1]
- Maintenance initiation timing: maintenance dose is initiated 24 hours after the loading dose. [1]
- Discontinuation: intravenous aspirin is continued until oral or nasogastric aspirin can be safely initiated. [1]
Acute coronary syndrome (ACS) evidence for IV dosing
- Single-dose 250 mg IV acetylsalicylic acid is associated with faster and more complete inhibition of thromboxane generation and platelet aggregation compared with 300 mg oral aspirin in an ACS mechanistic study. [3]
- Single-dose 500 mg IV acetylsalicylic acid is used in ACS studies to achieve rapid antiplatelet effects. [2]
- Administration technique in one healthy-volunteer pharmacokinetic study: IV lysine acetylsalicylate was dissolved and injected into a forearm vein within 1 minute. [5]
Administration and Preparation
Reconstitution and dilution (CHW)
- The 500 mg powdered aspirin vial is reconstituted with supplied water for injection immediately before use. [1]
- If supplied diluent is unavailable, water for injection may be used for reconstitution. [1]
- Brand-specific reconstitution volumes are specified in the protocol.
- Aspegic: add 5 mL water for injection to 500 mg acetylsalicylic acid lysine acetylsalicylate to yield 100 mg/mL. [1]
-
Bayer Aspirin IV: add 4.2 mL water for injection to 500 mg to yield 100 mg/mL. [1]
-
Dilution is performed into a compatible fluid (glucose 5%, Hartmann’s, or sodium chloride 0.9%). [1]
- The 500 mg dose is diluted to a maximum volume of 250 mL of compatible fluid. [1]
- Infusion duration: infused over at least 20 minutes. [1]
- The reconstituted solution is single use, with unused solution discarded. [1]
Contraindications
Intravenous aspirin is contraindicated with the following conditions (CHW policy): [1]
- Allergy to aspirin (acetylsalicylic acid) or excipients. [1]
- Aspirin-sensitive asthma. [1]
- Severe active bleeding. [1]
- Severe hepatic failure. [1]
- Disease states with increased risk of severe bleeding, including bleeding disorders and gastric ulcers. [1]
- Portal hypertension with esophageal varices. [1]
- Third trimester of pregnancy. [1]
Alternatives When Aspirin Is Contraindicated or Not Tolerable
Clopidogrel is used as an alternative antiplatelet when aspirin cannot be administered due to contraindication or intolerance. [4], [6] For reported aspirin hypersensitivity in ACS, aspirin desensitization is preferred whenever possible to allow initial use of dual antiplatelet therapy. [7]
Key Evidence Supporting Intravenous Aspirin Use
In an ACS mechanistic study, a single 250 mg IV dose produced faster and more complete inhibition of thromboxane generation and platelet aggregation than 300 mg oral aspirin. [3] In an ACS study design comparing IV lysine acetylsalicylate doses, IV aspirin (including 500 mg) has been used as an alternative route in patients unable to take oral aspirin. [2]
Common Pitfalls to Avoid
Reconstitution and infusion must follow protocol instructions for concentration, compatible diluents, and infusion duration to reduce medication preparation errors. [1] Bleeding risk requires explicit screening for severe active bleeding, bleeding disorders, and high-risk GI or variceal bleeding states before administration. [1]
Target Goals of Therapy
Intravenous aspirin is used to provide urgent platelet inhibition until oral or nasogastric aspirin can be safely initiated. [1] In ACS, intravenous aspirin administration is used to achieve rapid platelet inhibition when oral administration is not possible. [2], [3]